Lone atrial fibrillation in elderly persons: A marker for cardiovascular risk

Archives of Internal Medicine

Volumn 159, Issue 10, 1999, Pages 1118-1122

  Kopecky, Stephen L ^a   Gersh, Bernard J ^a   McGoon, Michael D ^a   Chu, Chu Pin ^a   Ilstrup, Duane M ^a   Chesebro, James H ^a,b   Whisnant, Jack P ^a  

^a MAYO CLINIC   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; STROKE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; MIDDLE AGED; MINNESOTA;

EID: 0033599966     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.10.1118     Document Type: Article

References (35)

1. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987; 317:669-674.
2. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham study. JAMA. 1985;254:3449-3453.
3. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
4. Wiebers DO, Whisnant JP, Sandok BA, O'Fallon WM. Prospective comparison of a cohort with asymptomatic carotid bruit and a population-based cohort without carotid bruit. Stroke. 1990;21:984-988.
5. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1968;50:163-170.
6. Kokmen E, Chandra V, Schoenberg BS. Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods, 1960-1974. Neurology. 1988;38:975-980.
7. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018-1022.
8. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973-977.
9. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke. 1983;14:664-667.
10. Roy D, Marchand E, Gangé P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J. 1986;112:1039-1043.
11. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thrombo-embolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;1:175-179.
12. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
13. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham study. Arch Intern Med. 1987;147:1561-1564.
14. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983-988.
15. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features of patients at risk. Ann Intern Med. 1992;116:6-12.
16. Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation. 1989; 80:1501-1513.
17. Stroke Prevention in Atrial Fibrillation Investigators (SPAF). Stroke Prevention in Atrial Fibrillation study: final results. Circulation. 1991;66:818-831.
18. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
19. Peyman MA. The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants. Acta Med Scand. 1958;162(suppl 339):1-62.
20. Pollard JW, Hamilton MJ, Christensen NA, Achor RWP. Problems associated with long-term anticoagulant therapy: observations in 139 cases. Circulation. 1962; 25:311-317.
21. Roos J, van Joost HE. The cause of bleeding during anticoagulant treatment. Acta Med Scand. 1965;178:129-131.
22. Sreerama V, Ivan LP, Dennery JM, Richard MT. Neurosurgical complications of anticoagulant therapy. CMAJ. 1973;108:305-307.
23. Coon WW, Willis PW III. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med. 1974;133:386-392.
24. Husted S, Andreasen F. Problems encountered in long-term treatment with anticoagulants. Acta Med Scand. 1976;200:379-384.
25. Davis FB, Estruch MT, Samson-Corvera EB, Voigt GC, Tobin JD. Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. Arch Intern Med. 1977;137:197-202.
26. Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J. 1979;42:128-132.
27. Second Report of the Sixty Plus Reinfarction Study Research Group (Wintzen AR, Tijssen JGP, de Vries WA, Loeliger EA, Roos J, ed comm). Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 1982;1:64-68.
28. Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med. 1986; 81:255-259.
29. O'Malley K, Stevenson IH, Ward CA, Wood AJJ, Crooks J. Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol. 1977;4: 309-314.
30. Shepherd AMM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977;4:315-320.
31. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med. 1988;148:1733-1736.
32. Petty GW, Lennihan L, Mohr JP, et al. Complications of long-term anticoagulation. Ann Neurol. 1988;23:570-574.
33. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet. 1994;343:687-691.
34. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262.
35. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. JAMA. 1998;279:1273-1277.